Earnings ·
Sana Biotechnology reports Q3 net income of $20.4M, or $0.07 per share
SANASana Biotechnology, Inc.
Sana Biotechnology reported a GAAP net income of $20.4 million for the third quarter ended September 30, 2026, translating to earnings of $0.07 per share. This marks a significant turnaround from the $42.2 million loss recorded in the same period last year. The result was primarily driven by non-cash gains totaling $63.4 million related to reductions in the estimated fair value of success payment liabilities and contingent consideration, largely stemming from an August 2026 amendment to the Cobalt acquisition agreement. Operating expenses included research and development costs of $33.9 million and general and administrative expenses of $10.9 million. The company ended the quarter with a cash position of $121.7 million, providing an expected runway into mid-2027. Sana Biotechnology is focused on creating and delivering engineered cells as medicines.